News
-
According to ARS Pharmaceuticals, both the US Patent and Trademark Office and the European Patent Office have upheld the validity of claims in patents related to neffy epinephrine nasal spray / EURneffy adrenaline nasal spray.… Read more . . .
-
Italian biotech NanoPhoria Bioscience announced that it has raised €83.5 million in Series A financing to support development of its NP-MP1 “lung-to-heart nano-in-micro technology.” The company notes that the €83.5 million funding is the largest… Read more . . .
-
AeroRx Therapeutics announced that it has closed a $21 million Series A financing to support continued development of the company’s AERO-007 indacaterol / glycopyrrolate inhalation solution for the treatment of COPD. In 2022, AeroRx announced… Read more . . .
-
Orexo announced that the US Biomedical Advanced Research and Development Authority (BARDA) has awarded the company $8 million to support the development of OX390, a new chemical entity formulated for nasal delivery for the reversal… Read more . . .
-
Leyden Laboratories announced that it has raised €30 million in equity financing from the European Innovation Council (EIC) Fund and Invest-NL to support development of its PanFlu intranasal human monoclonal antibody for the prevention and… Read more . . .
-
Inhaled drug developer Avalyn Pharma has announced the appointments of Jill Denning as Senior VP, Clinical Development Operations, and Kimberley Cummings as Senior VP, Regulatory Affairs. Denning was most recently VP of Clinical Development at Kinevant… Read more . . .
-
AstraZeneca has announced that it will sell the Airsupra albuterol / budesonide MDI directly to US patients through a web site called AstraZeneca Direct starting October 1, 2025. According to the company, patients with a… Read more . . .
-
ReCode Therapeutics said that the Cystic Fibrosis Foundation will provide an additional $3 million for development of RCT2100 inhaled mRNA therapy for CF and that the company has closed a funding of more than $29… Read more . . .
-
Tonix Pharmaceuticals has announced plans for a Phase 2 trial of its TNX-2900 intranasal magnesium-potentiated oxytocin in patients with Prader-Willi syndrome (PWS). According to Tonix, the FDA has already cleared the company’s IND for a… Read more . . .
-
Inhaled drug developer MannKind Corporation has announced the appointment of Ajay Ahuja as Executive VP and Chief Medical Officer. Ahuja was most recently Development and Launch Leader at Kardigan Bio; his previous experience includes executive roles at… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK